Bax、Bcl-2在局部晚期宫颈癌中的表达及意义.docVIP

精品论文 参考文献 Bax、Bcl-2在局部晚期宫颈癌中的表达及意义 夏红1 易建华2 杨丽1 褚桂芬1 　　(1广州市番禺区中心医院妇科 广东广州 511400) 　　(2中山大学附属第一医院黄埔院区 广东广州 510700) 　　【摘要】目的 探讨Bax、Bcl-2蛋白在局部晚期宫颈癌（LACC）中的表达及其临床意义。方法 应用免疫组化检测47例LACC 组织中化疗前Bax、Bcl-2蛋白的表达情况。结果 ①47例LACC中，NACT有效率为72.3%，CR 为14.9%。②化疗前，Bax及Bcl-2蛋白阳性表达率分别为:55.3%、36.2%。临床有效及无效病例中，Bax阳性表达率分别为64.7%、38.5%，差异有统计学意义（Plt;0.05）；Bcl-2阳性表达率分别为32.4%、46.2%，差异无统计学意义（Pgt;0.05）。③肿瘤低分化患者中Bax阳性表达率明显低于高中分化患者，有淋巴结转移者明显低于无淋巴结转移者（Plt;0.05）；而在年龄、病灶大小、病理类型、临床分期方面均无明显差异（Pgt;0.05）。Bcl-2 表达在各临床病理参数方面均无明显差异（Pgt;0.05）。结论 紫杉醇+顺铂静脉化疗对LACC有效，Bax蛋白异常表达与宫颈癌的生物学行为有关，可作为预测和判定NACT疗效的指标。 　　【关键词】宫颈肿瘤 化疗 细胞凋亡 Bcl-2蛋白 Bax蛋白 　　【中图分类号】R730.2 【文献标识码】A 【文章编号】2095-1752（2014）12-0026-02 　　Studies on the Expression and Clinical Significance of Bax and Bcl-2 before neoadjuvant chemotherapy in Locally advanced cervical cancer 　　Xia Hong1, Yi Jian-hua2, Yang Li1, Chu Gui -Fen1, 　　 Department of Obstetrics and Gynecology, Pan Yu central hospital, Guangzhou, 511400 　　【Abstract】Objective To investigate the expression and clinical significance of Bax and Bcl-2 before neo-adjuvant chemotherapy (NACT) in locally advanced cervical cancer (LACC) . Methods 47 patients with stage ⅠB2-ⅡB of LACC treated with neoadjuvant chemotherapy(NACT) between January 2010 and December 2013 in our hospital were retrospectively analyzed. The expressions of Bax and Bcl-2 were determined by means of immunohistochemistry before NACT. Results: The total effective rate of NACT was 72.3%, including CR 14.9%. The Bax and Bcl-2 expression was 55.3% and 36.2% before NACT. In patients who react and react poorly to NACT, the expression of Bax was 64.7% and 38.5% (plt;0.05), the expression of Bcl-2 was 32.4% and 46.2% (pgt;0.05). The staining intensity for Bax was related to histopathological grade and lymphatic metastasis (plt;0.05), but was not related to age, pathological type and clinical stage (Pgt;0.05). The staining intensity for Bcl-2 was not related to the above cl